Latest "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Stories

07:48 EST 21st December 2014 | BioPortfolio

Here are the most relevant search results for "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" found in our extensive news archives from over 250 global news sources.

More Information about Fluorouracil Leukovorin bevacizumab Colorectal Cancer on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Fluorouracil Leukovorin bevacizumab Colorectal Cancer for you to read. Along with our medical data and news we also list Fluorouracil Leukovorin bevacizumab Colorectal Cancer Clinical Trials, which are updated daily. BioPortfolio also has a large database of Fluorouracil Leukovorin bevacizumab Colorectal Cancer Companies for you to search.

Showing "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Articles 1–25 of 16,000+

Extremely Relevant

[News] FOLFOXIRI and bevacizumab in metastatic colorectal cancer

First-line bevacizumab with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) improves survival outcomes in patients with metastatic colorectal cancer, according to a new trial.

FOLFOXIRI plus bevacizumab ups outcome in metastatic CRC

(HealthDay)—For patients with untreated metastatic colorectal cancer, chemotherapy with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab improves outcome versus fluorouracil, leucovorin, and irinotecan (FOLFIRI) pl...

[Comment] Cetuximab or bevacizumab in metastatic colorectal cancer?

In The Lancet Oncology, Volker Heinemann and colleagues report the results of FIRE-3, a randomised phase 3 trial comparing cetuximab with bevacizumab, in combination with fluorouracil, folinic acid, and irinotecan (FOLFIRI), for the first-line treatm...

FOLFOXIRI + Bevacizumab Improves Outcomes for Metastatic Colorectal Cancer

According to a recent report in The New England Journal of Medicine, initial treatment with FOLFOXIRI plus Avastin® (bevacizumab), rather than FOLFIRI plus Avastin, improved progression-free survival in adults with inoperable metastatic colorectal c...

ESMO GI: Cetuximab or bevacizumab with combi chemo equivalent in KRAS wile-type metastic colorectal cancer

For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. “The...

Cetuximab delivers better overall survival than bevacizumab in metastatic colorectal cancer

by ecancer reporter Janet Fricker Patients with KRAS exon 2 wild type metastatic colorectal cancer achieve longer overall survival with FOLFIRI plus cetuximab than FOLFIRI plus bevacizumab, concluded the FIRE-3 trial published in Lancet Oncology. W...

CYRAMZA Phase III Second-Line Colorectal Cancer Trial Meets Primary Endpoint of Overall Survival

Ramucirumab Plus FOLFIRI Improved Survival in Metastatic Colorectal Cancer following Progression on a Bevacizumab-Based Regimen

Bcl-2 stabilization by paxillin confers 5-fluorouracil resistance in colorectal cancer

[News] UK Cancer Drugs Fund to reassess 42 agents

National Health Service (NHS) England has announced a re-evaluation of 42 drugs funded by the controversial Cancer Drugs Fund (CDF) based on cost-effectiveness. The drugs include bevacizumab for breast, ovarian, and colorectal cancer, cetuximab for c...

[Articles] FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

Although the proportion of patients who achieved an objective response did not significantly differ between the FOLFIRI plus cetuximab and FOLFIRI plus bevacizumab groups, the association with longer overall survival suggests that FOLFIRI plus cetuxi...

Cetuximab or bevacizumab with combi chemo equivalent in KRAS wild-type MCRC

(European Society for Medical Oncology) For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastroin...

[Articles] Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled tr

Adjuvant FOLFOX improves disease-free survival compared with fluorouracil plus leucovorin in patients with locally advanced rectal cancer after preoperative chemoradiotherapy and total mesorectal excision, and warrants further investigation.

Genetic testing of tumor is recommended for colorectal cancer patients

Of the 143,000 patients diagnosed with colorectal cancer annually in the U.S., up to 25 percent have a familial risk of colorectal cancer. A new guideline from the U.S. Multi-Society Task Force on Colorectal Cancer recommends genetic testing of tumor...

[News] Adenoma removal and colorectal cancer mortality

Patients who have low-risk adenomas removed have a reduced risk of dying from colorectal cancer compared with the general population, according to a new study. The researchers linked Norway's National Cancer Registry with its Cause of Death Registry...

Support for fecal testing in familial colorectal cancer screening

Fecal immunochemical tests (FIT) may be as effective as colonoscopies when it comes to detecting colorectal cancer among first-degree relatives of patients with colorectal cancer, according to a new study in Gastroenterology, the official journal of ...

[Articles] Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial

Despite prematurely terminated accrual and the lack of information about post-progression treatment, both progression-free survival and overall survival were significantly improved with bevacizumab and capecitabine compared with bevacizumab alone as ...

New clues for the early detection of colorectal cancer

Researchers at the University of Luxembourg have identified potential new ways to test for the first signs of one of the most deadly types of cancer: colorectal cancer. They have found new "biomarkers": molecules whose increased presence or absence i...

In Advanced Pancreatic Cancer, Eloxatin® with Folinic Acid and Fluorouracil May Improve Survival

In a Phase III study, the addition of the chemotherapy drug Eloxatin® (oxaliplatin) to the chemotherapy regimen of folinic acid and fluorouracil (5-FU) improved outcomes in patients with advanced pancreatic cancer that had progressed on Gemzar® (ge...

FDA OKs Bevacizumab (Avastin) for Late-Stage Cervical Cancer

The new indication for bevacizumab includes patients with cervical cancer that is persistent or recurrent. FDA Approvals

Breast, colorectal cancers remain more aggressive in children

Breast and colorectal cancers rarely occur in children, but when they do, these conditions are more precarious, according to a pair of National Cancer Data Base studies. Both breast cancer and colon cancer are known as adult conditions; 95 percent of...

Colorectal Cancer Partnering 2009-2014

Recently added to the BioPortfolio report store, Colorectal Cancer Partnering 2009-2014 is a new report from Current Partnering published on 2014-10-31. This 150+-page report is available from $995. The Colorectal Cancer Partnering 2009-2014 report provides understanding and access to the colorectal cancer partnering deals and agreements entered into by the worlds leading healthcare companies. T...

New discovery may advance colorectal cancer diagnosis and treatment

A Vanderbilt University-led research team has identified protein "signatures" of genetic mutations that drive colorectal cancer, the nation's second leading cause of cancer deaths after lung cancer.

Cologuard® for colorectal cancer screening

Cologuard®, is a multi-target stool screening test for colorectal cancer and advanced pre-malignant lesions, developed by Exact Sciences Corporation. It is intended for use as a screening test through the detection of mutated or altered DNA known to be associated with colorectal neoplasia or faecal haemoglobin. Cologuard® is intended for adults of either sex aged 50 years or older, who are at av...

Stand Up To Cancer and Dutch Cancer Society International colorectal cancer dream team

(Entertainment Industry Foundation) The international SU2C-Kankerbestrijding Molecular Early Detection of Colorectal Cancer Dream Team will be led by researchers from VU University Medical Center in Amsterdam and Johns Hopkins Sidney Kimmel Comprehen...

FDA Approves Bevacizumab for Recurrent Ovarian Cancer

Bevacizumab has received FDA approval for use in combination with chemotherapy in women with platinum-resistant, recurrent ovarian cancer. Medscape Medical News


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks